Health Care • Biotechnology: Pharmaceutical Preparations
$3.10 ▲ +0.00
(0.00%)
MKT CAP: $772.5M • VOL: 2.55M
52W L $3 52W H $8
ARDX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $407.3M | $333.6M | $124.5M |
| YoY Revenue Growth % | +22.1% | +168.1% | — |
| Gross Profit | $367.8M | $283.1M | — |
| Gross Margin % | 90.3% | 84.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$41.0M | -$27.9M | -$63.3M |
| Operating Margin % | -10.1% | -8.4% | -50.8% |
| Net Income (GAAP) | -$62.0M | -$39.0M | -$66.0M |
| EBITDA (Normalized) | -$39.8M | -$27.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$42.5M | -$44.8M | -$89.7M |
| Capital Expenditures (CapEx) | $1.5M | $1.0M | — |
| Free Cash Flow (FCF) | -$44.0M | -$45.8M | -$89.7M |
| FCF Margin % | -10.8% | -13.7% | -72.1% |
| Return on Invested Capital (ROIC %) | -32.7% | -20.4% | — |
| Cash & Short-Term Equivalents | $68.0M | $64.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $166.9M | $173.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ARDX.